Literature DB >> 8604808

Prostatic carcinoma with abundant xanthomatous cytoplasm. Foamy gland carcinoma.

R S Nelson1, J I Epstein.   

Abstract

Foamy gland carcinoma, an unusual variant of prostate carcinoma, is characterized by abundant xanthomatous cytoplasm. We studied 38 needle biopsies in which at least one core contained cancer with >20% foamy morphology. On average, each cancer was 72% foamy, and 11 cancers were entirely foamy. In addition to the characteristic cytoplasm, 20 cases had abundant intraluminal dense pink amorphous secretions. Nuclear enlargement and prominent nucleoli were either absent of rare in 23 (61%) and 27 (71%) of foamy gland carcinomas, respectively. High-molecular-weight cyto-keratin stains were done in 20 cases; 19 foamy gland carcinomas were negative, confirming the diagnosis of carcinoma and one case had keratin staining inconsistent with a known benign pattern. Of the 27 cases with associated ordinary gland carcinoma on needle biopsy, 26 (96%) were Gleason sum greater than 4. Subsequent radical prostatectomy (RP) and transurethral resection demonstrating cancer were available in 17 cases. Of the 15 subsequent RPs, only five were organ-confined and only one was Gleason sum less than 5. The cancers in the RP group ranged from 1 to 90% foamy (mean, 39%). Foamy gland carcinoma must be recognized as carcinoma by its abundant foamy cytoplasm, its architectural pattern of crowded or infiltrative glands, and frequently present pink acellular secretions. The more typical features of adenocarcinoma, nuclear enlargement and prominent nucleoli, are frequently absent. Its relatively benign cytology makes this lesion difficult to recognize as carcinoma; 74% of our cases were seen in consultation. Despite its benign cytology, foamy gland carcinoma is best classified as intermediate-grade carcinoma.

Entities:  

Mesh:

Year:  1996        PMID: 8604808     DOI: 10.1097/00000478-199604000-00004

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  8 in total

Review 1.  Diagnosis of adenocarcinoma in prostate needle biopsy tissue.

Authors:  P A Humphrey
Journal:  J Clin Pathol       Date:  2007-01       Impact factor: 3.411

Review 2.  The pathology of unusual subtypes of prostate cancer.

Authors:  Jing Li; Zhe Wang
Journal:  Chin J Cancer Res       Date:  2016-02       Impact factor: 5.087

3.  Case - Foamy, high-grade prostatic intraepithelial neoplasia: A false positive for prostate cancer on multiparametric magnetic resonance imaging?

Authors:  Thenappan Chandrasekar; Hanan Goldberg; Zachary Klaassen; Nathan Perlis; Antonio Finelli; Andrew Evans; Sangeet Ghai
Journal:  Can Urol Assoc J       Date:  2018-02-06       Impact factor: 1.862

4.  Expression and significance of cortactin and HDAC6 in human prostatic foamy gland carcinoma.

Authors:  Huilian Hou; Le Zhao; Wei Chen; Jing Li; Qinqin Zuo; Guanjun Zhang; Xuebin Zhang; Xu Li
Journal:  Int J Exp Pathol       Date:  2015-06-26       Impact factor: 1.925

Review 5.  Histopathology of Prostate Cancer.

Authors:  Peter A Humphrey
Journal:  Cold Spring Harb Perspect Med       Date:  2017-10-03       Impact factor: 6.915

6.  Patient with prostatic adenocarcinoma with plasmacytoid features and an aberrant immunohistochemical phenotype diagnosed by biopsy and a mini-review of plasmacytoid features in the genitourinary system: A case report.

Authors:  Konstantina Zacharouli; Dimitra P Vageli; George K Koukoulis; Maria Ioannou
Journal:  Mol Clin Oncol       Date:  2022-01-20

7.  Quantitative determination of expression of the prostate cancer protein alpha-methylacyl-CoA racemase using automated quantitative analysis (AQUA): a novel paradigm for automated and continuous biomarker measurements.

Authors:  Mark A Rubin; Maciej P Zerkowski; Robert L Camp; Rainer Kuefer; Matthias D Hofer; Arul M Chinnaiyan; David L Rimm
Journal:  Am J Pathol       Date:  2004-03       Impact factor: 4.307

8.  Case report: Papillary mesothelioma of the peritoneum with foamy cell lining.

Authors:  Simona Stolnicu; Enoe Quiñonez; Monica Boros; Claudiu Molnar; Isabel Dulcey; Francisco F Nogales
Journal:  Diagn Pathol       Date:  2013-09-25       Impact factor: 2.644

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.